|
| 36921494 | Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer. | | 2023 |
| 37903590 | Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial. | | 2023 |
| 34689413 | Extracellular vesicle production in Gram-positive bacteria. | Microbial Biotechnology | 2022 |
| 35364611 | Novel Anti-LY6G6D/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Colorectal Cancer. | Molecular Cancer Therapeutics | 2022 |
| 35416705 | Controlled Proteolysis of an Essential Virulence Determinant Dictates Infectivity of Lyme Disease Pathogens. | Infection and Immunity | 2022 |
| 36265119 | Tumor Fraction Correlates With Detection of Actionable Variants Across > 23,000 Circulating Tumor DNA Samples. | JCO Precision Oncology | 2022 |
| 35660252 | Immune contexture of paediatric cancers. | Eur J Cancer | 2022 |
| 35190375 | Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in mutated non-small cell lung cancer with , or comutations: subgroup results from the phase III IMpower150 trial. | Journal for ImmunoTherapy of Cancer | 2022 |
| 34433583 | Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition. | Gut | 2022 |
| 34972191 | Transcriptomic profiling of adjuvant colorectal cancer identifies three key prognostic biological processes and a disease specific role for granzyme B. | PLoS ONE | 2021 |
| 33637813 | Investigating BB0405 as a novel Borrelia afzelii vaccination candidate in Lyme borreliosis. | Scientific Reports | 2021 |
| 33241650 | Pan-cancer population pharmacokinetics and exposure-safety and -efficacy analyses of atezolizumab in patients with high tumor mutational burden. | Pharmacology Research and Perspectives | 2020 |
| 32103181 | Peripheral T cell expansion predicts tumour infiltration and clinical response. | Nature | 2020 |
| 30918950 | Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors. | Ann Oncol | 2019 |
| 31781549 | Enzymatic Bioremediation of Organophosphate Compounds-Progress and Remaining Challenges. | Frontiers in Bioengineering and Biotechnology | 2019 |
| 29934966 | Borrelia burgdorferi protein interactions critical for microbial persistence in mammals. | Cellular Microbiology | 2019 |
| 29350463 | BRIM-P: A phase I, open-label, multicenter, dose-escalation study of vemurafenib in pediatric patients with surgically incurable, BRAF mutation-positive melanoma. | Pediatric Blood and Cancer | 2018 |
| 29032550 | Analysis of Borrelia burgdorferi Proteome and Protein-Protein Interactions. | Methods in Molecular Biology | 2018 |
| 29991973 | Pseudoprogression of CNS metastatic disease of alveolar soft part sarcoma during anti-PDL1 treatment. | Radiology Case Reports | 2018 |
| 29763623 | Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial. | Cancer Cell | 2018 |
| 28963370 | Eukaryotic-type serine/threonine kinase mediated phosphorylation at Thr perturbs mycobacterial guanylate kinase activity. | Bioscience Reports | 2017 |
| 28592866 | A protein-protein interaction dictates Borrelial infectivity. | Scientific Reports | 2017 |
| 27271745 | HtrA, a Temperature- and Stationary Phase-Activated Protease Involved in Maturation of a Key Microbial Virulence Determinant, Facilitates Borrelia burgdorferi Infection in Mammalian Hosts. | Infect Immun | 2016 |
| 25542447 | Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype. | Cancer Discov | 2015 |
| 24335187 | Variola virus E3L Zα domain, but not its Z-DNA binding activity, is required for PKR inhibition. | RNA | 2014 |
| 24122209 | Mouse tumour models to guide drug development and identify resistance mechanisms. | Journal of Pathology | 2014 |
| 24352648 | Molecular pathways: response and resistance to BRAF and MEK inhibitors in BRAF(V600E) tumors. | Clinical Cancer Research | 2014 |
| 23302800 | Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. | Nature | 2013 |
| 24097822 | The evolution of melanoma resistance reveals therapeutic opportunities. | Cancer Research | 2013 |
| 23063529 | eIF2γ mutation that disrupts eIF2 complex integrity links intellectual disability to impaired translation initiation. | Molecular Cell | 2012 |
| 20303269 | Ajuba LIM proteins are negative regulators of the Hippo signaling pathway. | Current Biology | 2010 |
| 21382592 | A multifunctional lentiviral-based gene knockdown with concurrent rescue that controls for off-target effects of RNAi. | | 2010 |
| 20970745 | Regulation of U6 promoter activity by transcriptional interference in viral vector-based RNAi. | | 2010 |
| 18805675 | Evidence for the presence of R250G mutation at the ATPase domain of topoisomerase II in an arsenite-resistant Leishmania donovani exhibiting a differential drug inhibition profile. | International Journal of Antimicrobial Agents | 2009 |
| 18557704 | Ability of PknA, a mycobacterial eukaryotic-type serine/threonine kinase, to transphosphorylate MurD, a ligase involved in the process of peptidoglycan biosynthesis. | Biochemical Journal | 2008 |
| 17827231 | Endothelial cell migration on RGD-peptide-containing PEG hydrogels in the presence of sphingosine 1-phosphate. | Biophys J | 2008 |
| 18199749 | Interdomain interaction reconstitutes the functionality of PknA, a eukaryotic type Ser/Thr kinase from Mycobacterium tuberculosis. | J Biol Chem | 2008 |
| 17068335 | GTPase activity of mycobacterial FtsZ is impaired due to its transphosphorylation by the eukaryotic-type Ser/Thr kinase, PknA. | Journal of Biological Chemistry | 2006 |